These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18714439)

  • 21. Pharmacologic approaches to correcting the basic defect in cystic fibrosis.
    Lukacs GL; Durie PR
    N Engl J Med; 2003 Oct; 349(15):1401-4. PubMed ID: 14534332
    [No Abstract]   [Full Text] [Related]  

  • 22. The stony road to phe508del CFTR pharmacotherapy: smoothing the first rock.
    Tümmler B
    Lancet Respir Med; 2014 Jul; 2(7):508-9. PubMed ID: 24973279
    [No Abstract]   [Full Text] [Related]  

  • 23. Personalized medicine. New cystic fibrosis drug offers hope, at a price.
    Kaiser J
    Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790
    [No Abstract]   [Full Text] [Related]  

  • 24. Potentiators for cystic fibrosis - targeting the underlying molecular defect.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Paediatr Respir Rev; 2015 Jun; 16(3):162-4. PubMed ID: 26002404
    [No Abstract]   [Full Text] [Related]  

  • 25. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
    Aslam A; Jahnke N; Remmington T; Southern KW
    Paediatr Respir Rev; 2017 Sep; 24():32-34. PubMed ID: 28566196
    [No Abstract]   [Full Text] [Related]  

  • 26. Homozygosity for L997F in a child with normal clinical and chloride secretory phenotype provides evidence that this cystic fibrosis transmembrane conductance regulator mutation does not cause cystic fibrosis.
    Derichs N; Schuster A; Grund I; Ernsting A; Stolpe C; Körtge-Jung S; Gallati S; Stuhrmann M; Kozlowski P; Ballmann M
    Clin Genet; 2005 Jun; 67(6):529-31. PubMed ID: 15857421
    [No Abstract]   [Full Text] [Related]  

  • 27. Gentamicin in pharmacogenetic approach to treatment of cystic fibrosis.
    Hamilton JW
    Lancet; 2001 Dec; 358(9298):2014-6. PubMed ID: 11755605
    [No Abstract]   [Full Text] [Related]  

  • 28. A combination therapy for cystic fibrosis.
    Brodsky JL; Frizzell RA
    Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
    Birault V; Solari R; Hanrahan J; Thomas DY
    Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.
    Antoniu SA
    Expert Opin Investig Drugs; 2011 Mar; 20(3):423-5. PubMed ID: 21303308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential.
    Elborn JS; Davies J
    Lancet Respir Med; 2017 Sep; 5(9):681-683. PubMed ID: 28853396
    [No Abstract]   [Full Text] [Related]  

  • 34. Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy.
    Lubamba B; Dhooghe B; Noel S; Leal T
    Clin Biochem; 2012 Oct; 45(15):1132-44. PubMed ID: 22698459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cystic fibrosis and bone disease: defective osteoblast maturation with the F508del mutation in cystic fibrosis transmembrane conductance regulator.
    Velard F; Delion M; Le Henaff C; Guillaume C; Gangloff S; Jacquot J; Tabary O; Touqui L; Barthes F; Sermet-Gaudelus I
    Am J Respir Crit Care Med; 2014 Mar; 189(6):746-8. PubMed ID: 24628315
    [No Abstract]   [Full Text] [Related]  

  • 36. Ignoring the nonsense: a phase II trial in cystic fibrosis.
    Hyde SC; Gill DR
    Lancet; 2008 Aug; 372(9640):691-2. PubMed ID: 18722009
    [No Abstract]   [Full Text] [Related]  

  • 37. A breath of fresh air.
    Rowe SM; Clancy JP; Sorscher EJ
    Sci Am; 2011 Aug; 305(2):68-73. PubMed ID: 21827128
    [No Abstract]   [Full Text] [Related]  

  • 38. New therapies in cystic fibrosis.
    Ratjen F; Grasemann H
    Curr Pharm Des; 2012; 18(5):614-27. PubMed ID: 22229570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sweat chloride concentration in cystic fibrosis patients with cystic fibrosis trans-membrane conductance regulator 11234V mutation.
    Al-Mendalawi MD; Abdul-Wahab A; Janahi IA; Abdel-Rahman MO
    Saudi Med J; 2010 Mar; 31(3):339-40; author reply 340. PubMed ID: 20231949
    [No Abstract]   [Full Text] [Related]  

  • 40. Therapeutic benefit of ivacaftor in late cystic fibrosis caused by homozygous IVS8-5T CFTR polymorphism.
    Magne F; Durupt S; Nove-Josserand R; Bey-Omar F; Laoust L; Cottin V; Durieu I; Reynaud Q
    J Cyst Fibros; 2017 Jan; 16(1):89-90. PubMed ID: 27810230
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.